Torrent Pharmaceuticals

Torrent Pharmaceuticals Limited
Type	Public
Traded as	BSE: 500420
Industry	Pharmaceuticals
Founded	1959
Headquarters	Ahmedabad, India
Key people	Sudhir Mehta, Samir Mehta
Revenue	INR 7673 Cr (March 2019)
Net income	INR 436 Cr (March 2019)
Number of employees	14550 (2019)
Website	www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group. Based in the Indian city of Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals operates in more than 40 countries with over 2000 product registrations globally. Torrent Pharma is active in the therapeutic areas of Cardiovascular (CV), central nervous system (CNS), gastro-intestinal, diabetology, anti-infective and pain management segments. It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments. Drug firm Torrent Pharmaceuticals on 23 July 2019 reported a 32.51 percent rise in its consolidated net profit to Rs 216 crore for the quarter ended 30 June, mainly on account of robust sales in most geographies.[1]

Subsidiaries

It has 7 fully owned subsidiaries:

Heumann Pharma GmbH & Co Generica KG, Germany
Torrent Pharma GmbH, Germany
Torrent do Brasil Ltda., Brazil
ZAO Torrent Pharma, Russia
Torrent Pharma Inc., United States
Torrent Pharma Philippines Inc., Philippines
Torrent Pharma Canada Inc., Canada
Torrent Pharma UK United Kingdom

Torrent Pharmaceuticals acquired Heumann GmbH, a Pfizer company, in 2005.

Operations

The company's key areas are Formulations, API, Drug Discovery, Marketing and Sales of Drugs. Its operations locations are:

Manufacturing plant at Dahej, Gujarat
Manufacturing plant[2] at Pithampur[3], Madhya Pradesh
Manufacturing plant at Indrad, Mehsana, Gujarat
Manufacturing plant at Baddi, Himachal Pradesh
3 Manufacturing plant at Rang-Po,(Sikkim)
Research Centre, Ahmedabad-Gandhinagar region, Gujarat
Corporate Office, beside sales India, off. Ashram Road, [Ahmedabad]- Gujarat
Manufacturing plant at Visakhapatnam (Andhra Pradesh)

Recalls

In 2018, Torrent Pharmaceuticals recalled tablets containing valsartan[4][5] and losartan[6] due to the detection of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) respectively which are probable human carcinogens.

In September 2019, the FDA issued notice of a sixth product recall of losartan by Torrent Pharmaceuticals when certain batches of losartan contained the contaminant, N-methylnitrosobutyric acid (NMBA), above acceptable daily intake levels determined by the FDA.[7]

gollark: Fun-ruiner.

gollark: tio!leak_staff_messages

gollark: I know, it's ridiculous, I should be able to arbitrarily leak any staff messages if I want to.

gollark: I've been told that I can't go around randomly leaking staff actions, which is obviously ridiculous.

gollark: The palaiologos administration is *not* really very transparent.

References

"Torrent Pharma Q1 net profit up 33 percent to Rs 216 crore". Medical Dialogues. 23 July 2019.
Sunkara, Keshav (19 January 2018). "Torrent Pharma acquires US-based Bio-Pharm". VCCIRCLE. Retrieved 20 July 2019.
PTI (18 March 2016). "Torrent Pharma gets establishment nod from USFDA". The Economic Times. Retrieved 20 July 2019.
"Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets". 2018. Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
"FDA updates on valsartan recalls". 2018.
"Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP". 2018. Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
"Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP". US Food and Drug Administration. 23 September 2019. Retrieved 23 September 2019.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Torrent Pharma Q1 net profit up 33 percent to Rs 216 crore". Medical Dialogues. 23 July 2019.

[2] Sunkara, Keshav (19 January 2018). "Torrent Pharma acquires US-based Bio-Pharm". VCCIRCLE. Retrieved 20 July 2019.

[3] PTI (18 March 2016). "Torrent Pharma gets establishment nod from USFDA". The Economic Times. Retrieved 20 July 2019.

[ucm617821-4] "Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets". 2018. Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.

[ucm613916-5] "FDA updates on valsartan recalls". 2018.

[ucm628966-6] "Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP". 2018. Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.

[fda9-23-19-7] "Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP". US Food and Drug Administration. 23 September 2019. Retrieved 23 September 2019.